Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025
Provided By PR Newswire
Last update: Oct 20, 2025
Sirexatamab demonstrated statistically significant improvement in PFS and OS in DKK1-high population
Increasing DKK1 levels further improved PFS, OS, and ORR advantage for the Sirexatamab Arm
Read more at prnewswire.comNASDAQ:LPTX (10/22/2025, 11:31:43 AM)
0.4609
-0.02 (-5.09%)
Find more stocks in the Stock Screener
LPTX Latest News and Analysis
